Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA.
نویسندگان
چکیده
Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia.
منابع مشابه
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
Biosimilars are biological medicinal products that contain a version of the active substance of an already authorised original biological medicinal product (the innovator or reference product). The first approved biosimilar medicines were small proteins, and more recently biosimilar versions of innovator monoclonal antibody (mAb) drugs have entered development as patents on these more complex p...
متن کاملFDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz's Filgrastim Faces Naming and Court Hurdles.
As first biosimilar approval nears, key questions remain.
متن کاملCompatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study
INTRODUCTION Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelosuppressive chemotherapy. The primary goal of this VENICE study (ClinicalTrials.gov identifier, NC...
متن کاملBiosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies
Biosimilar drug products must have a demonstrated similarity with respect to the reference product's molecules in order to ensure both the effectiveness of the drug and the patients' safety. In this paper the fusion framework of a highly sensitive NMR fingerprinting approach for conformational changes and mathematically-based biosimilarity metrics is introduced. The final goal is to translate t...
متن کاملBiosimilars in the management of neutropenia: focus on filgrastim
Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human granulocyte colony-stimulating factor (G-CSF), filgr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 42 1 شماره
صفحات -
تاریخ انتشار 2017